Get the Stockscreener App
60.84
1.18%
0.68
Overview
News
Price History
Option Chain
Financials
Why BMY Down?
Discussions
Forecast
Stock Split
Dividend History
Bristol Myers Squibb Co stock is traded at $60.84, with a volume of 3.79M.
It is up +1.18% in the last 24 hours and up +12.73% over the past month.
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
See More
Previous Close:
$60.16
Open:
$60.08
24h Volume:
3.79M
Relative Volume:
0.34
Market Cap:
$124.28B
Revenue:
$48.48B
Net Income/Loss:
$7.27B
P/E Ratio:
17.08
EPS:
3.5626
Net Cash Flow:
$11.91B
1W Performance:
+6.89%
1M Performance:
+12.73%
6M Performance:
+11.69%
1Y Performance:
+30.38%
1-Day Range:
$59.80
$60.93
1-Week Range:
$57.04
$62.29
52-Week Range:
$42.52
$62.89
Bristol Myers Squibb Co Stock (BMY) Company Profile
Name
Bristol Myers Squibb Co
Sector
Industry
Phone
(609) 252-4621
Address
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
60.86 | 122.85B | 48.48B | 7.27B | 11.91B | 3.5626 |
LLY
Lilly Eli Co
|
1,166.08 | 1.02T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
249.84 | 598.96B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
256.07 | 447.67B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
126.09 | 307.25B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
154.29 | 285.37B | 54.66B | 13.58B | 16.05B | 7.0171 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-25-26 | Initiated | RBC Capital Mkts | Sector Perform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Upgrade | UBS | Neutral → Buy |
| Dec-15-25 | Upgrade | BofA Securities | Neutral → Buy |
| Dec-12-25 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Perform |
| Aug-05-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Apr-22-25 | Initiated | Piper Sandler | Overweight |
| Dec-16-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Nov-12-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-25-24 | Downgrade | Citigroup | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jul-29-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-11-24 | Downgrade | Societe Generale | Buy → Hold |
| Feb-06-24 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-15-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-27-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Oct-27-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Oct-27-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jul-10-23 | Initiated | SVB Securities | Market Perform |
| Jun-28-23 | Initiated | Daiwa Securities | Outperform |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Jan-17-23 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-18-22 | Initiated | Credit Suisse | Neutral |
| Oct-10-22 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-14-22 | Downgrade | Berenberg | Buy → Hold |
| Jun-03-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Underweight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Nov-01-21 | Downgrade | Argus | Buy → Hold |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-30-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-13-21 | Upgrade | Truist | Hold → Buy |
| Nov-16-20 | Upgrade | Societe Generale | Hold → Buy |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Nov-06-20 | Downgrade | Gabelli & Co | Buy → Hold |
| Oct-19-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Jul-28-20 | Initiated | Raymond James | Outperform |
| Apr-02-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-06-20 | Resumed | Citigroup | Buy |
| Dec-13-19 | Upgrade | Argus | Hold → Buy |
| Nov-22-19 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Aug-14-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| May-28-19 | Initiated | Goldman | Buy |
| May-20-19 | Downgrade | Argus | Buy → Hold |
| May-03-19 | Upgrade | Barclays | Equal Weight → Overweight |
| May-03-19 | Resumed | JP Morgan | Overweight |
| Jan-15-19 | Upgrade | Societe Generale | Sell → Buy |
| Oct-22-18 | Downgrade | Citigroup | Buy → Neutral |
View All
Bristol Myers Squibb Co Stock (BMY) Latest News
Bristol Myers Squibb stock trades steadily as oncology pipeline and recent earnings shape sentiment - Ad-hoc-news.de
BMS: Boosting AI Drug Discovery Capacity with NVIDIA Tech - Healthcare Digital
Bristol Myers Squibb Expands AI Infrastructure With NVIDIA to Build AI Factory for Drug Discovery - Digital Health News
BioNTech veröffentlicht am 4. August 2026 Ergebnisse für das zweite Quartal 2026 und informiert über operativen Fortschritt - GlobeNewswire Inc.
Bristol Myers Squibb buys Nvidia AI system for drug discovery - AI News
Bristol Myers Squibb stock trades steady as oncology pipeline and recent results frame investor focu - Ad-hoc-news.de
Bristol Myers Squibb (BMY) Expands AI Capabilities with Nvidia S - GuruFocus
BMS claims pharma's most powerful AI supercomputer. How it stacks up to Lilly's and Roche's. - drugdiscoverytrends.com
Bristol Myers Squibb (BMY) Enhances AI Capabilities with New NVI - GuruFocus
Bristol Myers Squibb stock steadies as investors weigh Opdivo growth and pending Karuna Therapeutics - Ad-hoc-news.de
BMS expands NVIDIA tie-up with Vera Rubin AI factory - The Pharma Letter
Bristol Myers Squibb stock holds steady as Eliquis and Opdivo underpin earnings outlook - Ad-hoc-news.de
Bristol Myers Squibb, NVIDIA build AI factory for drug discovery - MobiHealthNews
Alexandria Delivers R&D Hub for Bristol Myers Squibb at San Diego Megacampus - Connect CRE
Bristol Myers Squibb Expands AI Drug Discovery With NVIDIA Vera Rubin SuperPOD - AIM Media House
Bristol Myers Squibb expands Nvidia partnership to supercharge its AI drug factory - Crypto Briefing
Bristol Myers buys Nvidia's latest AI computing system for drug research - Reuters
Bristol Myers Squibb Expands Collaboration with Nvidia to Build AI Factory - Pharmaceutical Executive
BMS, Nvidia aim for ‘most powerful AI factory in life sciences’ - Fierce Biotech
Bristol Myers Squibb Supercharges Drug Discovery With NVIDIA AI - Benzinga
BMS again turns to NVIDIA to ramp up AI compute for drug discovery - FirstWord PHARMA
Alexandria delivers 427,000 sq ft R&D facility for Bristol Myers - Investing.com
Bristol Myers Squibb to build the most powerful AI factory in life sciences with NVIDIA - Chain Drug Review
Bristol Myers boosts AI capacity with expanded use of Nvidia systems - Seeking Alpha
Bristol Myers Squibb expands AI infrastructure with NVIDIA By Investing.com - Investing.com Nigeria
Nvidia partners with Bristol-Myers Squibb to build AI supercomputer for drug discovery - Crypto Briefing
Bristol Myers Squibb expands AI infrastructure with NVIDIA - Investing.com
Bristol Myers Squibb becomes latest company to claim it’s building pharma’s largest NVIDIA AI supercomputer - STAT
Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA - marketscreener.com
Bristol Myers Squibb stock trades steady as oncology focus meets mixed revenue trends - Ad-hoc-news.de
Bristol-Myers Squibb stock trades steady as Opdivo and Eliquis anchor earnings and pipeline focus - Ad-hoc-news.de
Bristol Myers Squibb stock trades steady as oncology and immunology portfolio underpins recent earni - Ad-hoc-news.de
Bristol Myers (BMY) Is Up 5.5% After FDA Accepts Mezigdomide NDA In Multiple Myeloma - simplywall.st
Bristol Myers Squibb stock trades steady as Revlimid erosion offsets Opdivo and Eliquis growth - ad-hoc-news.de
Bristol Myers Squibb Co (NYSE:BMY): A High Yield Dividend Stock Backed by Strong Profitability - ChartMill
Bristol Myers Squibb stock steadies as Opdivo and Eliquis underpin earnings power - ad-hoc-news.de
Bristol Myers Squibb stock trades steadily as Eliquis and Opdivo drive earnings and cash flow - ad-hoc-news.de
Bristol Myers Squibb stock trades steadily as cardiovascular and oncology portfolio supports earning - Ad-hoc-news.de
Bristol Myers Squibb stock trades steady as oncology and immunology portfolio underpins earnings - Ad-hoc-news.de
Is Bristol-Myers Squibb (BMY) Reasonable After Its 32% Run? - simplywall.st
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch
Bristol Myers Squibb stock trades steady as oncology revenue and Celgene legacy shape valuation - Ad-hoc-news.de
Bristol Myers Squibb stock trades steady as Q1 2026 results highlight stronger Eliquis and Opdivo re - Ad-hoc-news.de
Bristol Myers Squibb stock holds steady as oncology and immunology pipeline stays in focus for US in - Ad-hoc-news.de
Bristol-Myers Squibb stock holds steady as focus shifts to strategy - Ad-hoc-news.de
Bristol Myers Sues Generics Cos. Over Planned Cardiac Drug - Law360
Septa Pharmaceuticals Inc. Acquires CeeNU® (Lomustine) from Bristol Myers Squibb, Canada - Japan Wire by Kyodo News
Bristol-Myers Squibb Co Stock (BMY) Closed Up by 3.12% on Jul 15: Key Drivers Unveiled - TradingKey
Septa Pharmaceuticals Inc. Acquires CeeNU® (Lomustine) from Bristol Myers Squibb, Canada | Corporate - EQS News
Bristol-Myers Squibb Co (BMY) Shares Fall 4.0% -- What GF Score of 76 Tells Investors - GuruFocus
Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors - MarketWatch
Bristol Myers Squibb Co Stock (BMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.59%
1.96%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):